Policy & Regulation
Knopp Biosciences commences phase two trial of oral dexpramipexole
21 August 2019 -

Knopp Biosciences LLC, a drug discovery and development company, announced yesterday that it has commenced phase two dose-ranging clinical trial of oral dexpramipexole in moderate-to-severe eosinophilic asthma.

The company has started recruitment of patients and the first patient has been enrolled. It expects to report top-line data from this trial in the second half of 2020.

This 12-week biomarker study is planned to randomise around 100 patients with eosinophilic asthma to investigate the eosinophil response to three different doses of oral dexpramipexole. The primary result measure of this randomised, double-blind, placebo-controlled study is the change in blood absolute eosinophil count from Baseline to Week 12. The secondary outcome measures include changes in pre-bronchodilator FEV1 and asthma control outcomes (ACQ-7 questionnaire) from baseline to week 12.

Login
Username:

Password: